Table 1

 Demographics and baseline clinical characteristics of study population

Characteristic*Abatacept 2 mg/kg+etanercept (n = 85)Placebo+etanercept(n = 36)
CRP, C reactive protein; mHAQ, modified Health Assessment Questionnaire.
All patients received etanercept 25 mg twice weekly.
*Values are mean (SD), unless otherwise mentioned.
†68 joints were assessed for tenderness.
‡66 joints were assessed for swelling.
§Reference range 0–0.4 mg/dl.
Mean (years) age (range)49.8 (23–73)54.3 (28–71)
Women (%)7872
Caucasian (%)94100
Disease duration (years)13 (10.1)12.8 (8.6)
Tender joint count† (n)28.7 (14)29.2 (13.2)
Swollen joint count‡ (n)19.6 (9.4)20.1 (10.5)
Physical function,mHAQ score 0–31 (0.5)0.9 (0.5)
CRP level (mg/dl)§2 (2.7)2.4 (4.3)
Normal CRP level (%)(<2 mg/dl)6766.7